Upstream Bio posts corporate presentation highlighting verekitug Phase 3 plans in severe asthma, CRSwNP

Reuters2026/08/11 11:24

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Upstream Bio outlined plans to meet FDA in mid-2026, with Phase 3 starts in severe asthma and CRSwNP targeted for Q1 2027.
Pipeline centers on verekitug, a TSLP receptor antagonist, positioned for a single quarterly at-home injection using an autoinjector.
Phase 2 severe asthma data: 56% AAER reduction vs placebo (p<0.0003), 122 mL FEV1 improvement, 20.4 ppb FeNO reduction, 0.21 ACQ-6 reduction.
Phase 2 CRSwNP data: NPS reduction of -1.8 (p<0.0001), NCS reduction of -0.8 (p=0.0003), 76% lower surgery or steroid need (p=0.03).
COPD Phase 2 VENTURE enrollment completed, with data expected in H2 2027; existing capital expected to fund operations through 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Upstream Bio posts corporate presentation highlighting verekitug Phase 3 plans in severe asthma, CRSwNP

You may also like

Crypto prices